StockMarketWire.com - Angle reported Thursday that the first patient was enrolled into its clinical study for metastatic breast cancer.

The clinical study involved recruiting 200 metastatic breast cancer patients and 200 healthy volunteers enrolled at US cancer centres and was designed to support potential clearance by the FDA.

ANGLE Founder and Chief Executive, Andrew Newland, said: 'We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA Class II clearance for harvesting intact circulating tumor cells from patient blood for subsequent analysis.'

'This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy securing a leading position in the emerging multi-billion dollar liquid biopsy market.'

'The FDA clearance process is highly technically challenging. ANGLE has successfully met the many challenges involved in establishing the study and we are now into the next stage of executing the clinical study. We look forward to reporting further progress in due course.'







At 9:37am: [LON:AGL] Angle PLC share price was +2p at 49p



Story provided by StockMarketWire.com